Beta Finch - S&P 100 - EN cover art

Beta Finch - S&P 100 - EN

Beta Finch - S&P 100 - EN

Written by: Beta Finch
Listen for free

About this listen

 Top 100 US-listed companies by market capitalization. AI-powered earnings call analysis for S&P 100 (SP100). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.2026 Beta Finch Economics Personal Finance
Episodes
  • Intel Q1 2026 Earnings Analysis

    Intel Q1 2026 Earnings Analysis
    Apr 24 2026
    # Beta Finch Podcast Script - Intel Q1 2026 Earnings

    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex.

    **JORDAN:** And I'm Jordan. Today we're unpacking Intel's first quarter 2026 results, and wow - what a turnaround story this is becoming.

    **ALEX:** Before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Absolutely. Now Alex, let's talk about Intel because this earnings call felt like listening to a completely different company than we were hearing from just a year ago.

    **ALEX:** You're not wrong, Jordan. CEO Lip Bu Tan literally said "A year ago, the conversation about Intel Corporation was about whether we could survive. Today, it's about how quickly we can add manufacturing capacity." That's quite the transformation narrative.

    **JORDAN:** The numbers certainly back that up. Intel delivered $13.6 billion in revenue for Q1, which was $1.4 billion above the midpoint of their guidance. That's their sixth consecutive quarter of beating expectations. EPS came in at 29 cents versus guidance of breakeven.

    **ALEX:** And here's what really caught my attention - they're saying demand is outpacing supply across all their businesses, especially in server CPUs. CFO Dave Zinsner said they're missing out on revenue that "starts with a 'b'" - meaning billions in unmet demand.

    **JORDAN:** That supply constraint story is fascinating because it's driven by what they're calling the AI infrastructure buildout. Let's break down their segments. Data Center and AI revenue hit $5.1 billion, up 22% year-over-year, with ASIC revenue doubling. Meanwhile, Client Computing was $7.7 billion.

    **ALEX:** The AI story Intel is telling is particularly interesting. They're positioning CPUs as becoming more critical as AI moves from training to inference and into what they call "agentic" applications. Lip Bu mentioned that the ratio of CPUs to GPUs used to be 1-to-8, but it's moving toward 1-to-4 and could reach parity.

    **JORDAN:** That's a massive shift if it plays out. And they're backing it up with some big partnerships. They announced a multiyear deal with Google and this intriguing collaboration with Elon Musk's companies - SpaceX, xAI, and Tesla - for something called "TeraFab."

    **ALEX:** The Elon partnership is pretty wild. Lip Bu said they both believe global semiconductor supply isn't keeping pace with demand, and they want to "explore innovative ways to refactor silicon process technology." Very typical Elon - thinking outside the box on manufacturing efficiency.

    **JORDAN:** Let's talk about their foundry business because that's been the big question mark. Intel Foundry revenue was $5.4 billion, up 20% sequentially, though they're still losing $2.4 billion operationally. But here's the key - their 18A process node is running ahead of internal projections.

    **ALEX:** Right, and they're getting more confident about external foundry customers. Dave Zinsner said their advanced packaging backlog is now in the "billions of dollars" range, not the hundreds of millions they initially expected. That's a significant scale-up.

    **JORDAN:** The guidance for Q2 is solid too - $13.8 to $14.8 billion revenue, with both client and data center segments expected to grow sequentially. Though they are warning about PC market weakness in the second half and some margin pressure from ramping 18A production.

    **ALEX:** Speaking of margins, gross margin came in at 41% for Q1, way ahead of guidance, though they're guiding 39% for Q2. The 18A ramp is creating some near-term headwinds, but the volume growth and yield improvements are helping offset that.

    **JORDAN:** There was an interesting exchange in the Q&A about competi

    This episode includes AI-generated content.
    Show More Show Less
    8 mins
  • Thermo Fisher Scientific Q1 2026 Earnings Analysis

    Thermo Fisher Scientific Q1 2026 Earnings Analysis
    Apr 24 2026
    **BETA FINCH PODCAST SCRIPT**

    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the numbers that matter. I'm Alex.

    JORDAN: And I'm Jordan. Today we're diving into Thermo Fisher Scientific's Q1 2026 earnings, and let me tell you, this one's got some interesting moving parts.

    ALEX: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: Absolutely. So Alex, TMO just reported their first quarter results, and on the surface, it looks like a pretty solid performance. What caught your attention first?

    ALEX: Well, the headline numbers are decent but not spectacular. Revenue grew 6% to $11.01 billion, and adjusted EPS came in at $5.44, also up 6%. But here's the kicker - they actually beat their own guidance by 14 cents per share on the earnings side.

    JORDAN: That's a nice beat. And they're raising full-year guidance too, right? New revenue range of $47.3 to $48.1 billion, up from the previous $46.3 to $47.2 billion range.

    ALEX: Exactly. And on earnings, they're now expecting $24.64 to $25.12 per share, up from their original $24.22 to $24.80 guide. That represents 8% to 10% growth for the year. But Jordan, there's a big asterisk here - a lot of this guidance raise comes from their massive Clario acquisition.

    JORDAN: Right, the $9 billion elephant in the room. They closed that deal in late March. Clario is a digital endpoint data solutions company that complements their clinical research business. Even though it was only in the results for a few days, it contributed $30 million in revenue and a penny per share to Q1.

    ALEX: And CEO Marc Casper was pretty excited about it on the call. He kept talking about how it enhances their "trusted partner status" with pharma and biotech customers. The integration seems to be going smoothly, and customers are apparently enthusiastic about combining Thermo's capabilities with Clario's digital endpoints technology.

    JORDAN: Speaking of pharma and biotech, that was actually their strongest end market in the quarter with mid-single digit growth. Casper highlighted strength in bioproduction and clinical research. But let's talk about the headwinds they're facing.

    ALEX: Yeah, this is where it gets interesting. They had some real operational challenges. First, they had one less selling day compared to last year, which dinged organic growth by about a percentage point. Then there was revenue phasing in pharma services - another roughly one-point headwind.

    JORDAN: So if you normalize for those factors, their 1% organic growth in Q1 would have been closer to 3%. And that's exactly what they're guiding for in Q2. The concern from analysts on the call was about this acceleration they need in the back half of the year to hit their full-year 3-4% organic growth target.

    ALEX: Casper seemed pretty confident though. He said the markets are playing out exactly as expected, and the ramp isn't really assuming any change in underlying market conditions. It's more about these timing issues and comparisons normalizing.

    JORDAN: Let's break down the segments because there were some real divergences. Life Sciences Solutions was the star with 13% reported growth, though only 1% organic. That was driven by their bioproduction business having "another quarter of excellent organic growth," as CFO Stephen Williamson put it.

    ALEX: Meanwhile, Analytical Instruments was flat on revenue with organic declining 2%. This is the ongoing story we've been hearing across the industry - weak academic and government spending, especially in the US and China. Margins in that segment got hit hard, down 250 basis points to 20.7%.

    JORDAN: Ouch. And a lot of that margin pressure was from tariffs and foreign exchange headwinds. Williamson quantified the tariff

    This episode includes AI-generated content.
    Show More Show Less
    9 mins
  • ServiceNow Q1 2026 Earnings Analysis

    ServiceNow Q1 2026 Earnings Analysis
    Apr 24 2026
    # Beta Finch Podcast Script: ServiceNow Q1 2026 Earnings

    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into ServiceNow's Q1 2026 results, and wow - there's a lot to unpack here.

    **JORDAN:** There really is, Alex. And before we jump in, I want to make sure our listeners know that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **ALEX:** Thanks for that, Jordan. So let's start with the headline numbers because ServiceNow delivered what CEO Bill McDermott called a "beat and raise" quarter.

    **JORDAN:** Right, they beat across the board. Subscription revenue hit $3.67 billion, growing 19% year-over-year in constant currency - that's above the high end of their guidance. And their remaining performance obligations, or RPO, grew 23.5% to $27.7 billion. That's a massive backlog of contracted revenue.

    **ALEX:** The numbers are solid, but what's really interesting is the AI story here. McDermott dropped a pretty big bombshell on the call - they're now forecasting $1.5 billion in AI-specific commitments for 2026, up from their original $1 billion target. That's a 50% increase!

    **JORDAN:** That's huge, Alex. And it's not just talk - they're seeing real traction. Now Assist, their AI product suite, had deals with 3 or more products growing nearly 70% year-over-year. They had 36 deals with 5 or more AI products. Customers are clearly moving beyond just experimenting with AI.

    **ALEX:** Let's talk about their M&A strategy because they've been very active. They just closed three major acquisitions - Moveworks, Veza, and Armis. McDermott was particularly excited about the Moveworks integration.

    **JORDAN:** Yeah, the Moveworks story is pretty remarkable. They integrated it with their employee experience platform in just three weeks and rebranded it as "Employee Works." In Q1 alone, they closed more deals than Moveworks did in their entire previous year. That's execution at its finest.

    **ALEX:** And then there's Armis, which McDermott called their potential "Instagram" - referring to how that acquisition transformed Facebook. Armis brings cybersecurity visibility across IT, operational technology, and IoT devices. Given that cybercrime is now a trillion-dollar economy, the timing seems perfect.

    **JORDAN:** What I found fascinating was McDermott's framing of their "AI control tower for business reinvention." They're positioning ServiceNow as the orchestration layer that manages both human workers and AI agents. With 2.2 billion more AI agents expected in the workforce over the next few years, that's a massive opportunity.

    **ALEX:** The technical differentiation is interesting too. They're emphasizing their "context engine" - basically, 22 years of enterprise workflow data training their AI. As McDermott put it, "There's a perfect correlation between enterprise AI from any source and ServiceNow's expansion."

    **JORDAN:** Speaking of expansion, their hybrid pricing model is gaining traction. Fifty percent of new business now comes from non-seat-based pricing, including usage-based models. That's important because it lets them scale with AI adoption rather than just traditional user growth.

    **ALEX:** Now, let's address the elephant in the room - the stock dropped about 12% after hours despite these strong results. One analyst pressed them on this disconnect.

    **JORDAN:** Yeah, Keith Weiss from Morgan Stanley asked a great question about when ServiceNow will participate in the AI boom in a way that's more analogous to the big AI labs that are seeing massive revenue spikes. There seems to be some investor anxiety about whether ServiceNow is capturing enough of the AI spending.

    **ALEX:** McDermott's response was pretty passionate. He emphasized that t

    This episode includes AI-generated content.
    Show More Show Less
    9 mins
No reviews yet